The first time, scientific study has established that the response of natural killer (NK) cells is detrimental to glioblastoma virotherapy, a novel technique of treating malignant brain cancer by injecting a virus to the tumor.
A number of clinical trials are still underway to check whether glioblastoma virotherapy will facilitate antitumor efficacy, but research led by E. Antonio Chiocca, MD, PhD, chairman in the Department of Neurosurgery at Brigham and Women’s Hospital, and published naturally Medicine, implies that in pre-clinical models, NK cells are killing off of the virus – infected cells, thus rendering the therapy less capable.
“This situation is comparable to injecting an excellent drug right into a human and also the drug is got rid of because humans provide an antibody up against the drug,” said Dr. Chiocca, the senior author on the research paper. “This finding is going to be of great interest to people who definitely are studying experimental biology and tumors on the brain, as well as to patients with malignant brain tumors.”
Dr. Chiocca hypothesizes that temporarily suppressing the immune system of glioblastoma patients with a short-term basis could counteract this response and invite the virotherapy work. The learning could also expose novel targets to reinforce therapy.To learn more about the study, the full manuscript, “NK cells impede glioblastoma virotherapy via NKp30 and NKp46 natural cytotoxicity receptors”, can be purchased in Nature Medicine.
Source: Brigham and Women’s Hospital
Copyright 2012 Medimoon.com. All rights reserved. No part of this site can be reproduced without our written permission.